SIHUAN PHARM's self-developed innovative drug Dirocitin Tablets has been approved for market launch

AASTOCKS
2025.08.24 10:52

SIHUAN PHARM (00460.HK) announced that its non-wholly-owned subsidiary XuanZhu Bio's independently developed ALK inhibitor class 1 innovative drug Dirocitinib (trade name: XuanFeiNing) has been approved for marketing by the National Medical Products Administration of China for the treatment of advanced non-small cell lung cancer with anaplastic lymphoma kinase positivity. This is the third class 1 innovative drug approved for marketing by XuanZhu Bio and the second class 1 innovative oncology drug approved for marketing

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.